Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Status:
Active, not recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in
patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis
and psoriatic arthritis occurring together). The registry study will track the behavior of
the disease in response to other therapies, such as other biologic drugs. The registry will
also evaluate clinical outcomes; disease characteristics, including physician reported
assessment of psoriatic arthritis (PsA); quality of life, and potential risks for patients
who may receive standard therapies for psoriasis.